MXC: $0.073
What We Change

Holding unique IP, MGC Pharmaceutical’s Innovation division puts the Company at the forefront of exploration and development for indications that will serve large global markets.

As part of the Innovation division, MGC Pharma will be working on GMP certification and start clinical studies in epilepsy, based in Slovenia, in addition to ongoing advancement of supplement and neutraceutical products. MGC also hopes to offer patients in Australia with these products and generate revenue from API sales.

Research and Development
  • Longstanding clinical studies in Neurological disorders with Pro Uri Kramer and Dr. David Neubauer
  • Large pool of clinical data via management and advisory expertise
  • Unique patient care with Medical Cannabis
Business Development

Innovation Division: We will be working on GMP certification and commence clinical studies in epilepsy in Slovenia as well as continuing to work on the development of neutraceuticals and supplement products. We are also working on being able to provide patients in the Australian market with these products and generate revenue from API sales.

Projects
  • GMP Cleanroom operational
  • Active Analytical Laboratories operational
  • Sales and Production of the API in Europe
Partners
  • Data sharing with leading institutes and collaborations worldwide
  • Medicinal Cannabis Library with RMIT
  • Clinical Trials with the University of Ljubljana, Medical Faculty